Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG401 vs TPC in HR+/HER2- metastatic breast cancer
NCT06383767Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ESG401 in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative), sponsored by Qilu Pharmaceutical. Started Jul 2024; status: recruiting.
02
Drugs
ESG401
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT06383767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383767.